Implementing personalized cancer genomics in clinical trials

Area of Science:

• Genomics
• Oncology
• Clinical Trials

Background:

• High-throughput sequencing of cancer genomes is expanding molecular classification.
• This approach identifies predictive biomarkers for oncogene pathway activation.
• Biomarkers may guide patient selection for molecularly targeted therapies in clinical trials.

Purpose of the Study:

• To discuss challenges in adapting genomic data for rare cancers and molecular subsets.
• To highlight the need for aligning investigational agents with molecular profiling.
• To address considerations for clinical trial design and endpoints in precision oncology.

Main Methods:

• Review of current landscape of cancer genome sequencing and molecular classification.
• Discussion of challenges in clinical trial adaptation for specific cancer types.
• Analysis of requirements for integrating molecular data into trial design.

Main Results:

• Genomic studies have identified numerous biomarkers for targeted therapy selection.
• Significant challenges exist in applying these advances to rare cancers.
• Adapting trials requires addressing sequencing turnaround, agent availability, and eligibility criteria.

Conclusions:

• Molecularly targeted therapies offer promise, but access is limited for rare cancers.
• Clinical trial designs need adaptation to accommodate molecularly defined patient groups.
• Successful implementation requires a multidisciplinary approach involving sequencing, drug development, and trial design.